Bernard Taverne, Alice Desclaux, Papa Salif Sow

CHAPITRE II-1Diabète et hypertension artérielle : prévalence et facteurs associésird-00718213, version 1 - 16 Jul 201256. Crane HM, Van Rompaey SE, Kitahata MM. Antiretroviralmedications associated with elevated blood pressure amongpatients receiving highly active antiretroviral therapy. AIDS. 2006Apr 24;20(7):1019-26.57. Thiébaut R, El-Sadr WM, Friis-Møller N, Rickenbach M, ReissP, Monforte AD, et al; Data Collection of Adverse events of anti-HIVDrugs Study Group. Predictors of hypertension and changes ofblood pressure in HIV-infected patients. Antivir Ther.2005;10(7):811-23.58. Seaberg EC, Muñoz A, Lu M, Detels R, Margolick JB, RiddlerSA, et al; Multicenter AIDS Cohort Study. Association betweenhighly active antiretroviral therapy and hypertension in a largecohort of men followed from 1984 to 2003. AIDS. 2005 Jun10;19(9):953-60.59. Chow DC, Souza SA, Chen R, Richmond-Crum SM, GrandinettiA, Shikuma C. Elevated blood pressure in HIV-infectedindividuals receiving highly active antiretroviral therapy.HIV ClinTrials. 2003 Nov-Dec;4(6):411-6. Erratum in HIV Clin Trials. 2004Jan-Feb;5(1).60. Crane HM, Grunfeld C, Harrington RD, Kitahata MM. Lipoatrophyand lipohypertrophy are independently associated with hypertension.HIV Med. 2009 Sep;10(8):496-503. 2009 May 20.61. Cattelan AM, Trevenzoli M, Naso A, Meneghetti F, Cadrobbi P.Severe hypertension and renal atrophy associated with indinavir.Clin Infect Dis. 2000 Mar;30(3):619-21.62. Kane A, Ba SA, Sarr M, Diop BI, Hane L, Diallo TA, et al.[Arterial hypertension in Senegal: epidemiological aspects, clinicalfeatures, and therapeutic management problems]. Dakar Med.1995;40 (2):157-61.63. Gning SB, Thiam M, Fall F, Ba-Fall K, Mbaye PS, Fourcade L.Le diabète sucré en Afrique subsaharienne: aspects épidémiologiques,difficultés de prise en charge. Med Trop 2007 ; 67 : 607 –611.64. Yususf S, Ounpuu S pour le groupe des investigateursINTERHEART. Effect of potentially modifiable risk factors associatedwith myocardial infarction in 52 countries (the INTERHEARTstudy): case-control study. Lancet 2004, 364: 937-52.65. Duval X., Baron G., Garelik D., Villes V., Dupre T., Leport C., etal. Living with HIV, antiretroviral treatment experience and tobaccosmoking: results from a multisite cross-sectional study Antivir.Ther. 2008 ; 13 : 389-397.66. Devlin R.J., Henry J.A. Clinical review: major consequences ofillicit drug consumption Crit. Care 2008 ; 12 : 202.67. Lewden C., May T., Rosenthal E., Burty C., Bonnet F., CostagliolaD., et al. Changes in causes of death among adults infectedby HIV between 2000 and 2005: The "Mortalite 2000 and 2005"surveys (ANRS EN19 and Mortavic) J. Acquir. Immune Defic.Syndr. 2008 ; 48 : 590-598.68. Calmy A, Hirschel B, Hans D, Karsegard VL, Meier CA.Glitazones in lipodystrophy syndrome induced by highly activeantiretroviral therapy. AIDS. 2003 Mar 28;17(5):770-2.TABLEAU IPRINCIPALES CARACTÉRISTIQUESDES PATIENTS À LA DATE DU1ER DÉCEMBRE 2009Caractéristiques Effectif %Age 242Médiane (IIQ) 46 ans (40 – 54)< 45 ans 98 40,5Sexe 242Masculin 102 42,7IMC (kg/m 2 ) 242Médiane (IIQ) 22,3 (19,8 – 25,6)< 19 40 16,5Trithérapie de 2e ligne 242Oui 66 27,3Taux d’hémoglobine (g/dl) 233Médiane (IIQ) 12,9 (11,8 – 13,8)< 10 10 4,3Taux de CD4 (cellules/μL) 242Médiane (IIQ) 501 (372 – 722)> 200 229 94,6> 500 121 50,0Charge virale (copies/mL) 242Médiane (IIQ) 49 (49 – 49)< 50 201 83,1TABLEAU IIDURÉES D’EXPOSITIONAUX DIFFÉRENTES MOLÉCULES ARVMolécule Effectif Durée EcartARV exposé moyenne type(mois)AZT 173 52 45d4T 103 23 33ddI 156 50 483TC 240 88 32EFV 182 55 44NVP 77 22 47IDV 107 25 33LPV/r 61 7 1565